Galectin Therapeutics reported $61K in Ordinary Share Capital for its fiscal quarter ending in December of 2023.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Galectin Therapeutics USD 61K 0 Dec/2023
Gilead Sciences USD 1.24B 1000K Mar/2026
Immunic USD 120.38M 21.73M Dec/2025
Incyte USD 199.95M 1.49M Mar/2026
Merck USD 2.47B 12.72M Dec/2025